RecruitingObservationalLast updated Aug 12, 2026

The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial

Overview

ClinicalTrials.gov ID: NCT07761728
Lead Sponsor: University of California, Los AngelesOTHER
Brief Summary: This study seeks to evaluate if the diagnostic performance of 18F-flurpiridaz positron emission tomography (PET) myocardial perfusion imaging (MPI), given the radiotracer's properties, is non-inferior to the currently most widely utilized PET MPI radiopharmaceutical, 82Rb-chloride.
Study Type

Status

Study Record Dates

NCT01681524Withdrawn

Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI

NCT01347710Completed

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

NCT07284576Enrolling by invitation

Ultralow Dose PET Imaging of 18F-flurpiridaz

NCT04594941Completed

A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

NCT03354273Completed

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT05286593Completed

3D PET Myocardial Blood Flow and Rb82 Infusion Profiles